Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
Androgen deprivation therapy induces apoptosis and decreases both cell proliferation and angiogenesis in prostate adenocarcinoma. The molecular alterations following androgen ablation translate into unique cytologic features in both primary and metastatic prostate adenocarcinoma. We describe the cytologic appearance of metastatic prostate carcinoma following both surgical castration and androgen deprivation therapy.
Rapkiewicz
Amy
A
Department of Cytopathology, New York University, New York, USA. rapkia01@med.nyu.edu
Gorokhovsky
Rimma
R
Farcon
Eduardo
E
Das
Kasturi
K
D000230:Adenocarcinoma / Q000175:diagnosis / Q000473:pathology* / Q000556:secondary / Q000628:therapy; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000378:metabolism; D000813:Anilides / Q000627:therapeutic use; D044963:Biopsy, Fine-Needle; D003937:Diagnosis, Differential; D006652:Histological Techniques; D006801:Humans; D008297:Male; D009570:Nitriles / Q000627:therapeutic use; D009919:Orchiectomy; D011467:Prostate; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000601:surgery / Q000628:therapy; D014105:Tosyl Compounds / Q000627:therapeutic use
D000726:Androgen Antagonists; D000728:Androgens; D000813:Anilides; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D017430:Prostate-Specific Antigen